| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01126749 2009-015915-42 Details | 2022-02-28 Interventional | 1/2 | 92 | Gemcitabine Urinary Bladder… Bladder Cancer | Study was terminated as per sponsor's decision Due to the lack of a clear definition for PFS censoring rules and deviation from the statistical analysis plan relating to interim analyses, the PFS analysis was deemed unreliable and therefore data was not collected and reported. | |||
| NCT04525391 Details | 2022-02-25 Interventional | 2 | 4 | Durvalumab Small Cell Lung… SCLC, Recurrent | Recommended completion of the study due to SUSAR occurring in other clinical trials conducted
with the same drug. - | |||
| NCT04648319 Details | 2022-02-23 Interventional | 2 | 1 | Nivolumab Cholangiocarcin… | pharma company decision to withdraw the financial and IMP support - | |||
| NCT04539873 Details | 2022-02-23 Interventional | 3 | [4 Refs] | 128 | Colchicine Coronavirus Inf… Corona Virus In… | non-inclusion of patients in the study effectively - | ||
| NCT04832438 Details | 2022-02-22 Interventional | 2 | 0 | Carboplatin Carcinoma Carcinoma, Aden… Salivary Gland … Adenoid Cystic … Salivary Gland … Salivary Gland … | Replaced by NCT05010629 - | |||
| NCT04542434 Details | 2022-02-21 Interventional | 2 | 0 | Niclosamide COVID-19 Covid19 | Sponsor asset acquired by another pharma company who opened their own IND for this compound.
First Wave Bio never started this study in the US or ex-US. - | |||
| NCT04436458 Details | 2022-02-21 Interventional | 2 | 0 | Niclosamide COVID | Sponsor asset acquired by another pharma company who opened their own IND for this compound.
First Wave Bio never started this study in the US or ex-US. - | |||
| NCT03922477 Details | 2022-02-21 Interventional | 1 | 13 | Atezolizumab Magrolimab Leukemia Leukemia, Myelo… Leukemia, Myelo… Acute Myeloid L… | The Sponsor decided to discontinue the development of atezolizumab in combination with
magrolimab in the AML indication. - | |||
| NCT04363437 Details | 2022-02-18 Interventional | 2 | 21 | Colchicine Coronavirus Inf… Coronavirus Inf… | Stopped due to widespread corticosteroid use in 2020 for COVID infection, which confounds and
likely supercedes the effect of colchicine. - | |||
| NCT02954406 2016-001426-34 Details | 2022-02-18 Interventional | 1 | 43 | Bendamustine Hy… Gemcitabine Ibrutinib Lenalidomide Rituximab Lymphoma Lymphoma, Non-H… | Business decision, insufficient enrollment, no safety or efficacy concerns. - | |||
| NCT01606566 2011-003751-19 Details | 2022-02-18 Interventional | 2 | 26 | Bleomycin Carcinoma, Squa… Head and Neck N… Recurrence Squamous Cell C… Carcinoma, Squa… Recurrent Head … | Business reasons - | |||
| NCT00092833 Details | 2022-02-18 Interventional | 3 | 49 | Ezetimibe Hypercholestero… Hyperlipoprotei… Lipid Metabolis… Metabolism, Inb… Hypercholestero… | - - | |||
| NCT04498273 Details | 2022-02-17 Interventional | 3 | 657 | Apixaban Aspirin COVID-19 Thrombosis | an event rate lower than anticipated Early termination leads to a small number of subjects being analyzed. | |||
| NCT00651014 Details | 2022-02-17 Interventional | 4 | 82 | Ezetimibe Atherosclerosis Hypercholestero… | slow subject recruitment and lack of medical and scientific merit due to change in new standard
of therapy during that same period. - | |||
| NCT05242926 Details | 2022-02-16 Interventional | 1 | 0 | Docetaxel Solid Tumor, Ad… | Pending further development - | |||
| NCT02153645 Details | 2022-02-16 Interventional | 3 | 87 | Amantadine Dyskinesias Parkinson Disea… Levodopa Induce… Parkinson's Dis… | - - | |||
| NCT02153632 Details | 2022-02-16 Interventional | 3 | 135 | Amantadine Dyskinesias Parkinson Disea… Levodopa Induce… Parkinson's Dis… | - - | |||
| NCT02013141 Details | 2022-02-16 Interventional | 4 | 22 | Telavancin Bacterial Infec… Gram-Positive B… | FDA waived the pediatric study requirement for this application - | |||
| NCT01773083 2012-003289-42 Details | 2022-02-16 Interventional | 3 | 13 | Calcium heparin Heparin Respiratory Asp… Wounds and Inju… Burn Injury Inhalation Inju… | insufficient recruitment of patients and high costs associated with the purchase and blinding
of study medication - | |||
| NCT00423176 Details | 2022-02-16 Interventional | 3 | 237 | Anti-Bacterial … Antibiotics, An… Sinusitis | Based on business priorities. Not related to any safety or efficacy issue & took place before
data were unblinded or analyzed The study was terminated early due to a very high screening failure rate (mainly caused by the necessity to demonstrate CT changes at baseline indicative of acute sinusitis), which limits any conclusions. |